Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-Treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02129075
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:24.625389+00:00
Published At
2021-11-16T00:00:00+00:00
Record Updated At
2021-11-16
Results Posted At
2021-11-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cutaneous Melanoma", "Melanoma", "Melanoma of Unknown Primary", "Mucosal Melanoma", "Ocular Melanoma", "Stage IIB Cutaneous Melanoma AJCC v6 and v7", "Stage IIC Cutaneous Melanoma AJCC v6 and v7", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-11-16"
protocolSection.identificationModule.nctId
"NCT02129075"
protocolSection.identificationModule.officialTitle
"A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-Treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2021-11-16"

Study condition terms

  • Cutaneous Melanoma (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Melanoma of Unknown Primary (protocolSection.conditionsModule.conditions)
  • Mucosal Melanoma (protocolSection.conditionsModule.conditions)
  • Ocular Melanoma (protocolSection.conditionsModule.conditions)
  • Stage IIB Cutaneous Melanoma AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage IIC Cutaneous Melanoma AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage III Cutaneous Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Cutaneous Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Cutaneous Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Cutaneous Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Cutaneous Melanoma AJCC v6 and v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.